^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

AREG expression

i
Other names: AREG, AREGB, SDGF, Amphiregulin
Entrez ID:
Related biomarkers:
14d
Single-cell RNA sequencing analysis of vestibular schwannoma reveals functionally distinct macrophage subsets. (PubMed, Br J Cancer)
Macrophages form an important component of VS stroma. scRNAseq reveals three distinct subsets of macrophages in the VS tissue which may have differing roles in the pathogenesis of VS.
Journal
|
AREG (Amphiregulin) • CD163 (CD163 Molecule) • SPP1 (Secreted Phosphoprotein 1) • PLCG2 (Phospholipase C Gamma 2) • CD14 (CD14 Molecule) • CD68 (CD68 Molecule) • CSF1R (Colony stimulating factor 1 receptor) • IL1B (Interleukin 1, beta) • ALOX15 (Arachidonate 15-Lipoxygenase) • PLAUR (Plasminogen Activator, Urokinase Receptor)
|
AREG expression • CD163 expression
4ms
Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. (PubMed, BMC Cancer)
In RAS wt mCRC patients receiving EGFR-targeted therapy, BRAF mutation is a powerful prognostic and therapy-predictive biomarker, with no effect found for PIK3CA mutation, PTEN mutation or deletion, but the combined biomarker KRAS/NRAS/BRAF/PIK3CA mutations predict resistance to anti-EGFR therapy. Low miR-31-3p expression may have positive prognostic and therapy predictive effects. Evidence on the prognostic and predictive roles of EGFR and its ligands, and HER2/3/4 is insufficient.
Retrospective data • Review • Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • EREG (Epiregulin) • MIR31 (MicroRNA 31)
|
KRAS mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • HER-2 expression • PTEN mutation • ERBB3 expression • RAS mutation • RAS wild-type • ERBB3 mutation • PIK3CA mutation + PTEN mutation • AREG expression • ERBB4 expression • KRAS deletion
5ms
Amphiregulin Induces iNOS and COX-2 Expression through NF-κB and MAPK Signaling in Hepatic Inflammation. (PubMed, Mediators Inflamm)
AREG-activated NF-κB and MAPKs signaling, and together with NF-κB and MAPKs inhibitors, AREG significantly reduced the protein expression of iNOS and COX-2. AREG plays a role in hepatic inflammation by increasing iNOS and COX-2 expression via NF-κB and MAPKs signaling.
Journal
|
EGFR (Epidermal growth factor receptor) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • AREG (Amphiregulin) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • IL1B (Interleukin 1, beta) • MAPK8 (Mitogen-activated protein kinase 8)
|
AREG expression • PTGS2 expression • IL6 expression
6ms
A novel selective ERK1/2 inhibitor, Laxiflorin B, targets EGFR mutation subtypes in non-small-cell lung cancer. (PubMed, Acta Pharmacol Sin)
Finally, Laxiflorin B-4, a C-6 analog of Laxiflorin B, exhibited higher binding affinity for ERK1/2 and stronger tumor suppression. These findings provide a new approach to tumor inhibition using natural anticancer compounds.
Journal
|
EGFR (Epidermal growth factor receptor) • EREG (Epiregulin)
|
EGFR mutation • AREG expression
7ms
New P2 trial • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus) • AREG (Amphiregulin) • EREG (Epiregulin)
|
BRAF wild-type • AREG expression
|
Erbitux (cetuximab) • irinotecan
7ms
Dimethylarsinic acid induces bladder carcinogenesis via the amphiregulin pathway. (PubMed, Toxicol Lett)
RNA interference of human amphiregulin (AREG) expression in human urinary bladder cell lines T24 and UMUC3 decreased expression of AREG and its 6 target genes and decreased cell proliferation. These data suggest that Areg has an important role in DMA-induced rat bladder carcinogenesis.
Journal
|
AREG (Amphiregulin) • CCNA2 (Cyclin A2) • MKI67 (Marker of proliferation Ki-67) • PRC1 (Protein regulator of cytokinesis 1)
|
AREG expression
8ms
Clinical • P2 data
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • AREG (Amphiregulin) • EREG (Epiregulin)
|
KRAS wild-type • BRAF wild-type • AREG expression
|
5-fluorouracil • Vectibix (panitumumab) • leucovorin calcium
9ms
Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer. (PubMed, Clin Cancer Res)
High tumor AREG/EREG expression was associated with superior survival outcomes from anti-EGFR therapy in mCRC, including in right PTL disease. AREG/EREG IHC assessment could aid therapeutic decisions in routine practice.
Journal • Metastases
|
AREG (Amphiregulin) • EREG (Epiregulin)
|
RAS wild-type • AREG expression
|
Erbitux (cetuximab) • Vectibix (panitumumab) • oxaliplatin • irinotecan
10ms
THERAPY TAILORING IN GASTRIC CANCER: IDENTIFICATION OF BIOMARKERS OF RESPONSE TO ANTI-EGFR TREATMENTS (EACR 2023)
When the tumor of the cohort reached an average volume of 250mm3, mice were treated or not with cetuximab...HER3 targeting (by means of the novel antibody drug conjugate patritumab deruxtecan) and AREG/EREG silencing strongly affected cell viability, suggesting that sensitive models rely on these pathways for their growth.ConclusionWe identified a subset of GEA sensitive to EGFR targeting drugs and propose HER3 and AREG/EREG expression as markers for patients' selection. Further validation on GEA samples derived from clinical trials evaluating effectiveness of EGFR targeting is needed. We believe that, despite the negative results of clinical trials so far, EGFR can represent a suitable target in molecularly selected GEA patients.
ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • AREG (Amphiregulin) • EREG (Epiregulin)
|
ERBB3 expression • ERBB3 overexpression • AREG expression
|
Erbitux (cetuximab) • patritumab deruxtecan (U3-1402)
10ms
RACING: RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov)
P1/2, N=54, Completed, Hellenic Cooperative Oncology Group | Active, not recruiting --> Completed | Trial primary completion date: Jun 2023 --> Jun 2022
Trial completion • Trial primary completion date • Metastases
|
PTEN (Phosphatase and tensin homolog) • FLT1 (Fms-related tyrosine kinase 1) • SPARC (Secreted Protein Acidic And Cysteine Rich) • THBS1 (Thrombospondin 1) • EREG (Epiregulin) • MMP2 (Matrix metallopeptidase 2) • VEGFB (Vascular Endothelial Growth Factor B) • MMP9 (Matrix metallopeptidase 9)
|
EGFR mutation • PTEN mutation • AREG expression • FLT1 expression
|
gemcitabine • albumin-bound paclitaxel • Cyramza (ramucirumab)
1year
LncRNA TRG-AS1 inhibits bone metastasis of breast cancer by the miR-877-5p/WISP2 axis. (PubMed, Pathol Res Pract)
TRG-AS1 knockdown markedly reduced the number of TRAP+ cells and the percentage of Ki-67+ cells and decreased E-cadherin expression in xenograft tumor mice. In summary, TRG-AS1 acts an endogenous RNA, inhibited breast cancer bone metastasis by competitively binding with miR-877-5p to upregulate WISP2 expression.
Journal
|
CDH1 (Cadherin 1) • AREG (Amphiregulin) • CTSK (Cathepsin K) • NFATC1 (Nuclear Factor Of Activated T Cells 1) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • RUNX2 (RUNX Family Transcription Factor 2) • TNFSF11 (TNF Superfamily Member 11) • TRG (T Cell Receptor Gamma Locus)
|
CDH1 expression • AREG expression
1year
Comparison of Effects on the Tumor Microenvironment Between Sorafenib and Lenvatinib Treatment in Hepatocellular Carcinoma (APASL 2023)
Our study demonstrated different effects on the TME reshaping by sorafenib and lenvatinib. Additionally, enhanced expression of AREG might contribute to attenuation of antitumor immunity in sorafenib treatment. 1012
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • AREG (Amphiregulin) • GZMB (Granzyme B)
|
AREG expression
|
sorafenib • Lenvima (lenvatinib)
1year
The role of amphiregulin in ovarian function and disease. (PubMed, Cell Mol Life Sci)
Understanding the normal and pathological roles of AREG and elucidating the molecular and cellular mechanisms of AREG regulation of ovarian functions will inform innovative approaches for fertility regulation and the prevention and treatment of ovarian diseases. Therefore, this review summarizes the functional roles of AREG in ovarian function and disease.
Review • Journal
|
EGFR (Epidermal growth factor receptor) • AREG (Amphiregulin)
|
AREG expression
1year
Prostate cancer expressing membrane-bound TGF-α induces bone formation mediated by the autocrine effect of prostaglandin E in osteoblasts. (PubMed, Biochem Biophys Res Commun)
In co-culture of osteoblasts and fixed PC3 cells, the phosphorylation of EGFR and ERK and subsequent Ptgs2 expression and PGE production were increased, an effect that was attenuated by treatment with inhibitors of EGFR and ERK. These results indicate that membrane-bound TGF-α enhances ERK signaling while also inducing PGE-mediated bone formation in osteoblasts, thus suggesting that prostate cancer regulates both PGE-mediated bone resorption and bone formation at the site of bone metastasis of prostate cancer.
Journal
|
EGFR (Epidermal growth factor receptor) • AREG (Amphiregulin) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA) • RUNX2 (RUNX Family Transcription Factor 2)
|
AREG expression • PTGS2 expression
over1year
Association between artificial intelligence (AI) -assisted tumor AREG and EREG immunohistochemistry (IHC) and outcomes from anti-EGFR therapy during the routine management of metastatic colorectal cancer (mCRC): An observational cohort study. (ASCO-GI 2023)
AI assisted IHC evaluation of tumor AREG/EREG expression predicted benefit from anti-EGFR therapy in a retrospective analysis of the PICCOLO trial of second-line irinotecan ± panitumumab... Patients (pts) with available archival FFPE tumor tissue who received panitumumab or cetuximab ± chemotherapy at any time for treatment of mCRC at 8 UK cancer centers were eligible... High tumor AREG/EREG expression was associated with significantly prolonged PFS, OS and DCR among a cohort of pts treated with anti-EGFR therapy during routine care of mCRC. The prognostic effect observed validates the predictive effect of AREG/EREG seen in the PICCOLO trial, where AREG/EREG had no prognostic effect in patients receiving chemotherapy alone. A prospective biomarker-led trial is in set-up to support the use of AREG/EREG IHC in clinical practice.
Observational data • Metastases
|
BRAF (B-raf proto-oncogene) • AREG (Amphiregulin) • EREG (Epiregulin)
|
RAS mutation • AREG expression
|
Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
over1year
Donor-Derived Amphiregulin Drives CD4+ T Cell Expansion and Promotes Tissue Pathology after Experimental Allogeneic BMT (ASH 2022)
In summary, we found that CD4+ T cell-derived Areg contributes to CD4+ T cell proliferation after activation, leading to increased T cell expansion, tissue damage, and GVHD-related mortality after allo-BMT. Careful inhibition of the T cell Areg/EGFR axis may represent a novel therapeutic target for prevention or amelioration of GVHD.
IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • AREG (Amphiregulin) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
|
IFNG expression • AREG expression
over1year
Nuclear AREG affects a low-proliferative phenotype and contributes to drug resistance of melanoma. (PubMed, Int J Cancer)
According to the hypothesis, we detected the accumulation of AREG in the nucleus of SK-Mel-28-VR, which was cultured under Vemurafenib (VR) selection pressure, and this correlates with JARID1B expression. Here, knockdown of AREG makes the previously resistant cells more sensitive to VR treatment, resulting in inhibited proliferation. Taken together, we suggest that nuclear AREG affects a slow-cycling phenotype and increases resistance to VR, raising a possibility that AREG might be a potential therapeutic target for resistance in melanoma.
Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • AREG (Amphiregulin) • ARID1B (AT-Rich Interaction Domain 1B) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • SETDB1 (SET Domain Bifurcated Histone Lysine Methyltransferase 1) • KDM5B (Lysine Demethylase 5B)
|
AREG expression
|
Zelboraf (vemurafenib)
over1year
Pan-cancer distribution of cleaved cell-surface amphiregulin, the target of the GMF-1A3 antibody drug conjugate. (PubMed, Antib Ther)
Using 370 specimens from 10 tumor types (as well as normal controls), we demonstrate that cleaved amphiregulin is widely expressed in solid tumors and is especially common (> 50% of cases) in breast, prostate, liver and lung cancer. As a potential companion diagnostic for this antibody-drug conjugate, this assay allows identification of tumors with high levels of the cleaved amphiregulin target.
Journal • Pan tumor
|
EGFR (Epidermal growth factor receptor) • AREG (Amphiregulin) • ADAM17 (ADAM Metallopeptidase Domain 17)
|
AREG expression
over1year
RACING: RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov)
P1/2, N=54, Active, not recruiting, Hellenic Cooperative Oncology Group | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
Trial completion date • Trial primary completion date
|
PTEN (Phosphatase and tensin homolog) • FLT1 (Fms-related tyrosine kinase 1) • SPARC (Secreted Protein Acidic And Cysteine Rich) • THBS1 (Thrombospondin 1) • EREG (Epiregulin) • MMP2 (Matrix metallopeptidase 2) • VEGFB (Vascular Endothelial Growth Factor B) • MMP9 (Matrix metallopeptidase 9)
|
EGFR mutation • PTEN mutation • AREG expression • FLT1 expression
|
gemcitabine • albumin-bound paclitaxel • Cyramza (ramucirumab)
over1year
Proposing a combinatorial treatment modality for Epithelial Ovarian Cancer by untangling the relations between p53 mutations, PD-L1 functions and Amphiregulin abundance (EACR 2022)
Material and Methods 5×10 6 cells of ID8; ID8 p53 -/-, ID8 p53 -/- R175H and ID8 p53 -/- R273H were injected into C57BL/6 female mice, followed by 6 weeks of injections with anti-AREG (AR37) and anti-PD-L1 (Avelumab) 400µg/ mouse, twice a week...Conclusion Elucidating the varied response of EOC to monotherapies, we aim at evaluating an anti-AREG antibody in conjunction with PD-L1 therapy for synergistic effect. Our aim is to develop a safe and efficacious combinatorial therapy addressing the complexity of AREG and PD-L1 expression in EOC onset and progression.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • IFNG (Interferon, gamma) • AREG (Amphiregulin)
|
PD-L1 expression • TP53 mutation • AREG expression • TP53 R172H • TP53 R273H • PD-L1 mutation
|
Bavencio (avelumab)
2years
Establishment of a patient-derived mucoepidermoid carcinoma cell line with the CRTC1-MAML2 fusion gene. (PubMed, Mol Clin Oncol)
The results predicted that AREG-EGFR signaling, which is required for tumor growth and survival, might be activated in the cell line in a cell-autonomous manner. As AREG expression is associated with EGFR-targeted drug resistance, this cell line might assist with the identification of novel strategies for MEC treatment.
Preclinical • Journal
|
AREG (Amphiregulin) • CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
AREG expression • CRTC1-MAML2 fusion
2years
Microglial-stimulation of glioma invasion involves the EGFR ligand amphiregulin. (PubMed, PLoS One)
Interfering with ERK using pharmacological inhibitors prevents AREG upregulation in microglia and microglia-stimulated GL261 invasion. These data highlight AREG as a key factor in produced by tumor associated microglia in promoting glioma invasion.
Journal
|
EGFR (Epidermal growth factor receptor) • AREG (Amphiregulin)
|
AREG expression
2years
RETROSPECTIVE ANALYSIS ON THE ROLE OF BIOMOLECULAR MARKERS IN LOCO-REGIONALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMAS, TREATED WITH CHEMORADIOTHERAPY OR RADIOTHERAPY AND CETUXIMAB, PRECEDED OR NOT BY INDUCTION CHEMOTHERAPY (AIOM 2021)
Materials and The GSTTC study is a non-profit, Italian, multicentre, phase III factorial trial in which 414 patients with loco-regionally advanced Head and Neck Squamous Cell Carcinomas (LAHNSCC) were randomized to receive radiotherapy plus concomitant chemotherapy or cetuximab, preceded or not by induction docetaxel, cisplatin and 5- fluorouracil (TPF). HPV positivity and bcl-2 overexpression significantly correlated with PFS and OS in LAHNSCC. It is of interest the role of PD-L1 as, in its absence, immunotherapy loses most of its effectiveness while chemotherapy, in the context of PD-L1 negative cells, acquires the maximum ability to kill cancer cells.
Retrospective data • PD(L)-1 Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BIRC5 (Baculoviral IAP repeat containing 5) • EREG (Epiregulin) • BAX (BCL2-associated X protein)
|
PD-L1 negative • BCL2 overexpression • BCL2 expression • AREG expression • BAX expression
|
Erbitux (cetuximab) • cisplatin • docetaxel • 5-fluorouracil
over2years
Propofol induces apoptosis and ameliorates 5‑fluorouracil resistance in OSCC cells by reducing the expression and secretion of amphiregulin. (PubMed, Mol Med Rep)
Moreover, the results indicated that the expression and activation of AREG was also related to 5‑FU resistance, but propofol ameliorated 5‑FU drug resistance. Therefore, the present study suggested that propofol combination therapy may serve as an effective treatment strategy for OSCC.
Journal
|
EGFR (Epidermal growth factor receptor) • AREG (Amphiregulin)
|
AREG expression
|
5-fluorouracil
over2years
The Amphiregulin/EGFR Axis Regulates Donor T Cell Expansion and Contributes to Intestinal Gvhd Pathology after Allogeneic Bone Marrow Transplantation (TCT-ASTCT-CIBMTR 2022)
In summary, we found that CD4 + T cell-derived Areg contributes to their proliferation after activation, leading to increased T cell expansion, tissue damage and GVHD-related mortality after allo-BMT. Careful inhibition of the Areg-EGFR axis in T cells may represent a novel therapeutic target for prevention or amelioration of GVHD.
IO biomarker
|
AREG (Amphiregulin) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
|
AREG expression
over2years
RACING: RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov)
P1/2, N=54, Active, not recruiting, Hellenic Cooperative Oncology Group | Recruiting --> Active, not recruiting | Trial completion date: Sep 2021 --> Jul 2022 | Trial primary completion date: Sep 2021 --> Jun 2022
Clinical • Enrollment closed • Trial completion date • Trial primary completion date
|
PTEN (Phosphatase and tensin homolog) • FLT1 (Fms-related tyrosine kinase 1) • SPARC (Secreted Protein Acidic And Cysteine Rich) • THBS1 (Thrombospondin 1) • EREG (Epiregulin) • MMP2 (Matrix metallopeptidase 2) • VEGFB (Vascular Endothelial Growth Factor B) • MMP9 (Matrix metallopeptidase 9)
|
EGFR mutation • PTEN mutation • AREG expression • FLT1 expression
|
gemcitabine • albumin-bound paclitaxel • Cyramza (ramucirumab)
over2years
Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling. (PubMed, Cancer Lett)
Long-term mitochondrial inhibitor treatments-mediated mitochondrial stress adaptation could induce letrozole resistance...Moreover, mitochondrial stress adaptation-increased intracellular levels of reactive oxygen species (ROS) and calcium were shown to induce AREG expression and secretion. In conclusion, our results support the claim that mitochondrial stress adaptation contributes to AI resistance via ROS/calcium-mediated AREG-ERα loop signaling and provide possible treatment targets for overcoming AI resistance.
Journal
|
EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • AREG (Amphiregulin)
|
ER expression • AREG expression
|
letrozole
over2years
Expression of Amphiregulin in Enchondromas and Central Chondrosarcomas. (PubMed, Clinics (Sao Paulo))
Amphiregulin did not help in distinguishing enchondromas from low-grade chondrosarcomas. The present study is the first to document the expression of this immunohistochemical marker in enchondromas. Furthermore, amphiregulin expression in enchondromas was localized in short bones, indicating a phenotypic distinction from that in long bones. This distinction may contribute to an improved understanding of the pathogenesis of these lesions.
Journal
|
EGFR (Epidermal growth factor receptor) • AREG (Amphiregulin)
|
AREG expression
over2years
DDX3 modulates the tumor microenvironment via its role in endoplasmic reticulum-associated translation. (PubMed, iScience)
Finally, OSCC-associated mutant DDX3 increased the expression of AREG, emphasizing the role of DDX3 in tumor progression via SRP-dependent, endoplasmic reticulum-associated translation. Therefore, pharmacological targeting of DDX3 may inhibit the tumor-promoting functions of the TME.
Journal
|
AREG (Amphiregulin)
|
AREG expression
almost3years
Identification of Monocytes Associated with Severe COVID-19 in the PBMCs of Severely Infected patients Through Single-Cell Transcriptome Sequencing. (PubMed, Engineering (Beijing))
In conclusion, our study discovered two novel severe-disease-specific monocyte subsets as potential predictors and therapeutic targets for severe COVID-19. Overall, this study provides potential predictors for severe disease and therapeutic targets for COVID-19 and thus provides a resource for further studies on COVID-19.
Clinical • Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • AREG (Amphiregulin) • EREG (Epiregulin) • IL18 (Interleukin 18)
|
AREG expression
almost3years
Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53. (PubMed, Oncogene)
Consistent with these observations, analysis of OvCa patients revealed that high AREG correlates with poor prognosis of patients expressing wildtype TP53. In conclusion, clinical tests of the novel antibody are warranted; high AREG, normal TP53, and reduced CXCL1 activity might identify patients with OvCa who may derive therapeutic benefit.
Journal
|
TP53 (Tumor protein P53) • AREG (Amphiregulin) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
|
TP53 expression • AREG expression
almost3years
Evaluating the value of Amphiregulin, Phosphatase and Tensin Homologue (PTEN) and P21 Expression for Anti-EGFR Treatment in Metastatic Colorectal Carcinoma. (PubMed, Asian Pac J Cancer Prev)
High Amphiregulin and PTEN expression levels and low P21 expression levels were associated with better response to anti-EGFR therapy and improved survival outcome. They might be considered predictive markers of response to anti-EGFR therapy in mCRC. .
Journal
|
PTEN (Phosphatase and tensin homolog) • AREG (Amphiregulin) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
PTEN expression • PTEN-L • AREG expression
almost3years
Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer. (PubMed, Growth Factors)
In the subset of patients who received an EGFR inhibitor, EREG positivity was associated with longer OS (median 34.0 vs. 27.0 months, p = 0.033), driven by a difference in patients with a left-sided primary (HR 0.37, p = 0.015). Our study supports further investigation into EREG as a predictive biomarker in mCRC.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • AREG (Amphiregulin) • EREG (Epiregulin)
|
AREG expression
|
Erbitux (cetuximab) • Vectibix (panitumumab)
3years
Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel. (PubMed, Ann Oncol)
RAS-wt patients with left-PTL are more likely to have panitumumab PFS advantage than those with right-PTL or rectal-PTL. However, an extended biomarker panel demonstrated significant heterogeneity in panitumumab PFS effect within a tumor location. AREG/EREG and HER3 mRNA expression identifies patients with right-PTL or rectal-PTL who achieve similar PFS effect with panitumumab as left-colon patients. Testing could provide a more reliable basis for clinical decision-making. Further validation and development of these biomarkers is required to optimise routine patient care.
Clinical • P3 data • Journal
|
BRAF (B-raf proto-oncogene) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • AREG (Amphiregulin) • EREG (Epiregulin)
|
ERBB3 expression • AREG expression
|
Vectibix (panitumumab) • irinotecan
over3years
[VIRTUAL] Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. (ASCO-GI 2021)
A retrospective biomarker study within the PICCOLO trial (NCT00389870; irinotecan [Ir] ± Pan in fluoropyrimidine-resistant RAS-wt mCRC). IHC assessment of AREG and EREG identified pts who did or did not benefit from Pan, as has been previously demonstrated through mRNA quantification. IHC represents a more practicable technique as it can be provided at the point of care and is associated with shorter turn-around times. AREG and EREG IHC may be of use in routine practice to identify patients who would benefit from anti-EGFR therapy and those for whom alternative treatment strategies should be explored.
P3 data
|
BRAF (B-raf proto-oncogene) • AREG (Amphiregulin) • EREG (Epiregulin)
|
BRAF mutation • AREG expression
|
Vectibix (panitumumab) • irinotecan
over3years
Amphiregulin retains ERα expression in acquired aromatase inhibitor resistant breast cancer cells. (PubMed, Endocr Relat Cancer)
RNA-sequencing and reverse phase protein array analyses revealed that AREG maintains ERα expression and signaling by activation of PI3K/Akt/mTOR signaling and upregulation of forkhead box M1 (FOXM1) and serum- and glucocorticoid-inducible kinase 3 (SGK3) expression. Our study uncovers a previously unappreciated role of AREG in maintaining ERα expression and signaling, and establishes the AREG-ERα crosstalk as a driver of acquired AI resistance in breast cancer.
Journal
|
EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • AREG (Amphiregulin)
|
ER positive • AREG expression
over3years
miR-149 suppresses breast cancer metastasis by blocking paracrine interactions with macrophages. (PubMed, Cancer Res)
In vivo, lung metastases developing from orthotopic MDA-MB-231 tumors were reduced by 75% by miR-149 expression and this was associated with impaired M2 macrophage infiltration of the primary tumors. These data suggest that miR-149 downregulation functionally contributes to breast tumor progression by recruiting macrophages to the tumor and facilitating CSF1 and EGF receptor crosstalk between cancer cells and macrophages.
Journal
|
AREG (Amphiregulin) • CSF1 (Colony stimulating factor 1)
|
AREG expression